Cargando…
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 dia...
Autores principales: | Hiramatsu, Takeyuki, Ito, Hiroki, Okumura, Shota, Asano, Yuko, Iguchi, Daiki, Furuta, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919219/ https://www.ncbi.nlm.nih.gov/pubmed/33371732 http://dx.doi.org/10.1177/1479164120971220 |
Ejemplares similares
-
Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019) -
Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Banjara, Bidur, et al.
Publicado: (2022) -
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020) -
Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors
por: Hiramatsu, Takeyuki, et al.
Publicado: (2018) -
Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2023)